logo

Exclusive Market Insight

& Scientific analysis

subscribe today
  • Exclusive Posts
  • Industry Newsletters
  • Clinical Trials
  • Possible Takeovers
  • Technology of the Week
  • Stock Table
  • Therapeutic Vaccines
  • Development-Stage Firms
  • Genomics
  • Prohost Picks
  • And much more...
Trick or TradeToday’s HighlightsProhost LettersNews & CommentsImpacting NewsContact
Login

Category: News & Comments

AstraZeneca: Excellent collaborations. Moderna Therapeutics: Turning public. Will Prohost add it to its Portfolio as promised?

In the NEWS AstraZeneca (AZN) announced a collaboration with Cancer Research UK to launch a center of excellence in genetic screening, cancer modelling and big data processing aimed at accelerating the discovery of new cancer medicines. During the announcement of...

Read More

December 14, 2018

0

Portola: The FDA Approves Bevyxxa

After years of spending efforts in creating and developing its pipeline products,  Portola (PTLA)  has just been granted a U.S. Food and Drug Administration’s (FDA) approval of its Prior Approval Supplement (PAS) for the anticoagulant product  Bevyxxa® (betrixaban) . The product is...

Read More

December 19, 2017

0

The Gilead and Galapagos Agreement Is a Big Win for Both Firms and Their Shareholders

Gilead and Galapagos Global Research Collaboration Gilead Sciences ( GILD )   and Galapagos NV ( GLPG )   entered into a 10-year global research and development collaboration. Gilead will gain access to innovative compounds, including six molecules currently in...

Read More

July 15, 2019

0

The FDA Grants Fast Track Status to DelMar Pharmaceuticals’ Product VAL-083

The FDA Grants Fast Track Status to DelMar Pharmaceuticals’ Product VAL-083 Dec.26, 2017 –  DelMar Pharmaceuticals (DMPI)  announced that the U.S. Food and Drug Administration (FDA) has granted Fast Track designation for the company’s lead product candidate,  VAL-083 , in...

Read More

December 27, 2017

0

Agenus: Signing a lucrative and rewarding agreement with Gilead

Agenus (AGEN) announced recently that it entered into an immuno-oncology (I-O) partnership with Gilead Sciences (GILD) . The partnership is focused on developing and commercializing up to five novel I-O  therapies. The terms of the agreement Agenus is entitled to...

Read More

December 20, 2018

0

The FDA Approved Aerie Pharmaceuticals’ Glaucoma Eye Drops Rhopressa. What’s Next?

Two months ahead of the PDUFA date scheduled for February 28, 2018, the Food and Drug Administration (FDA) approved  Aerie Pharmaceuticals’ (AERI)   ophthalmic solution) 0.02% Rhopressa ®  (netarsudil for the lowering of elevated intraocular pressure (IOP) in open-angle glaucoma....

Read More

December 22, 2017

0

Cellectis: Offering Proof of Concept is What Led to the Stock Rally

UCART19 UCART19  is one of the  Cellectis’ (CLLS)  lead  allogeneic anti-CD19 CAR T-cell products . The word  allogeneic  is important as it makes the difference between Cellectis’ CAR T products and the two approved chimeric antigen receptor (CAR T) products...

Read More

December 14, 2017

0

Gilead: On the road towards realizing its goals. A new collaboration for fibrotic diseases

Gilead Sciences (GILD) and  Scholar Rock Holding Corporation   ( SRRK)  announced entering into a strategic collaboration to discover and develop highly specific inhibitors of transforming growth factor beta (TGFβ) activation for the treatment of fibrotic diseases. Under the terms of...

Read More

December 26, 2018

0

Halozyme and argenx Most Recent News

Halozyme and argenx Collaboration argenx ( ARGX )   dosed the first subject in phase 1 clinical trial for the safety, pharmacokinetics, and pharmacodynamics of its product efgartigimod plus Halozyme's ( HALO ) drug delivery technology ENHANZE ® . The...

Read More

July 19, 2019

0

Progenics: The FDA Accepted the NDA for Its Cancer Product Azedra® and Granted It Priority Review

Progenics Pharmaceuticals (PGNX)  has good news today. The U.S. Food and Drug Administration (FDA) has accepted for review the firm’s New Drug Application (NDA) for its product  Azedra®  for recurrent and/or unresectable  pheochromocytoma and paraganglioma  — rare neuroendocrine tumors. The FDA has also granted...

Read More

December 28, 2017

0

  • Previous
  • 1
  • 2
  • ...
  • 61
  • 62
  • 63
  • ...
  • 115
  • 116
  • Next

Search ProhostBiotech

Popular Links

23andMe Holding Co (ME)Abbott Laboratories (ABT)AbbVie Inc (ABBV)AbCelleraAbeona Therapeutics (ABEO)Ablynx (ABLX)AbVitro IncAcadia (ACAD)Acceleron Pharma (XLRN)AcelRx Pharmaceuticals (ACRX).Acorda Therapeutics Inc (ACOR)Acumen Pharmaceuticals (ABOS)AdaptImmune Therapeutics (ADAP)Adaptive BiotechnologiesADC Therapeutics (ADCT)Adimab LLCAdvanced Micro Devices (AMD)Advaxis (ADXS)Adverum Biotechnologies (ADVM)Aerie Pharmaceuticals (AERI)AgenTus TherapeuticsAgenus (AGEN)AgeX Therapeutics (AGE)Agilent Technologies (A)Agilis Biotherapeutics IncAgios Pharmaceuticals (AGIO)AIM ImmunoTech (AIM)Aimmune Therapeutics (AIMT)Akari Therapeutics (AKTX)Akashi TherapeuticsAkcea Therapeutics (AKCA)Akebia Therapeutics Inc (AKBA)Akero Therapeutics (AKRO)Akous Inc (a wholly owned subsidiary of Eli Lilly Company)Alder BioPharmaceuticals (ALDR)Alexion Pharmaceuticals (ALXN)Alkermes (ALKS)Allergan Plc (AGN)Allogene TherapeuticsAllogene Therapeutics (ALLO)

Recent

AstraZeneca Product Fasenra Approved in the US for Eosinophilic Granulomatosis with Polyangiitis 

September 19, 2024

0

The U.S. FDA Approves Novartis' Kisqali® to Reduce the Risk of Recurrence in People with HR+/HER2- Early Breast Cancer

September 18, 2024

0

AstraZeneca’s Imfinzi + Imjudo Demonstrated Unprecedented Overall Survival in Advanced Liver Cancer

September 17, 2024

0

Halozyme Therapeutics Announced FDA Approval of Roche’s Tecentriq Hybreza with ENHANZE

September 13, 2024

0

Johnson & Johnson Product TREMFYA® Receives U.S. FDA Approval

September 12, 2024

0

Prohost Biotech – Exclusive Biotech Research Copyright © 2026.
Privacy Policy